Senti Biosciences, Inc. (NASDAQ:SNTI) Short Interest Down 22.7% in April

Senti Biosciences, Inc. (NASDAQ:SNTI) saw a significant drop in short interest during the month of April. As of April 15th, there was short interest totalling 165,200 shares, a drop of 22.7% from the March 31st total of 213,800 shares. Based on an average daily trading volume, of 81,400 shares, the short-interest ratio is presently 2.0 days. Approximately 0.6% of the shares of the company are sold short.

Institutional Investors Weigh In On Senti Biosciences

A number of large investors have recently added to or reduced their stakes in the stock. 8VC GP I LLC purchased a new position in shares of Senti Biosciences in the 4th quarter worth $1,675,000. ARK Investment Management LLC lifted its holdings in Senti Biosciences by 7.9% in the fourth quarter. ARK Investment Management LLC now owns 1,969,860 shares of the company’s stock valued at $1,300,000 after acquiring an additional 143,785 shares during the period. Finally, TD Asset Management Inc boosted its position in Senti Biosciences by 88.4% in the third quarter. TD Asset Management Inc now owns 241,208 shares of the company’s stock worth $102,000 after purchasing an additional 113,172 shares during the last quarter. Institutional investors own 25.73% of the company’s stock.

Senti Biosciences Price Performance

NASDAQ SNTI traded up $0.02 during trading hours on Monday, hitting $0.31. The company’s stock had a trading volume of 43,472 shares, compared to its average volume of 104,664. Senti Biosciences has a 12 month low of $0.27 and a 12 month high of $1.10. The company’s 50 day simple moving average is $0.37 and its two-hundred day simple moving average is $0.41. The company has a market cap of $14.17 million, a P/E ratio of -0.19 and a beta of 2.96.

Senti Biosciences (NASDAQ:SNTI) last announced its quarterly earnings results on Thursday, March 21st. The company reported ($0.42) EPS for the quarter. Senti Biosciences had a negative return on equity of 74.59% and a negative net margin of 2,692.82%. As a group, research analysts predict that Senti Biosciences will post -1 earnings per share for the current fiscal year.

About Senti Biosciences

Senti Biosciences, Inc operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications.